Conavi Medical Inc (formerly Colibri Technologies), a company that develops, manufactures, sells, and supports technologies to help guide minimally invasive procedures, has announced that it has received FDA 510(k) clearance for its first commercial product, the Foresight ICE system for intracardiac echocardiography.
According to Conavi Medical, the Foresight ICE system is designed for intracardiac and intraluminal ultrasound visualization of cardiac and great vessel anatomy, as well as visualization of other devices in the heart and great vessels of patients. The catheter-based ultrasound system is capable of providing both 2D and 3D ultrasound images of cardiac anatomy around the circumference of the catheter’s tip. The system includes the dual display Conavi Hummingbird imaging console and the Foresight ICE catheter. These products can be used to support minimally invasive cardiovascular procedures performed in the US, such as ablations and other procedures that may require access to targeted regions of the heart.
“FDA clearance of the Foresight ICE system represents a major milestone for Conavi’s team and our customers in the US healthcare system,” said Brian Courtney, CEO of Conavi Medical Inc. “We look forward to working with physicians in the United States by providing them with new visualization tools to support existing and emerging minimally invasive procedures for patients with a broad range of cardiac conditions. The Foresight ICE system represents Conavi’s lead product in its commercialization pipeline.”
Conavi Medical Inc is reportedly commercializing technologies initially invented at Sunnybrook Research Institute in Toronto. The company’s focus is on providing image guidance technologies for minimally invasive procedures, with an initial emphasis on cardiovascular procedures.
For more information about the Foresight ICE system, visit the Conavi Medical website.